

December 26, 2023. No comments were received.

Obtaining Copies: Requesters may obtain a copy of the information collection documents from the GSA Regulatory Secretariat Division, by calling 202-501-4755 or emailing GSARegSec@gsa.gov. Please cite OMB Control No. 9000-0205, Implementation of Federal Acquisition Supply Chain Security Act (FASCSA) Orders.

Janet Fry,

*Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.*

[FR Doc. 2024-04505 Filed 3-1-24; 8:45 am]

BILLING CODE 6820-EP-P

UNITED STATES AGENCY FOR GLOBAL MEDIA

Fiscal Year (FY) 2022 Service Contract Inventory Report & FY 2023 Planned Analysis

AGENCY: United States Agency for
Global Media.

ACTION: Notice.

SUMMARY: The United States Agency for
Global Media (USAGM) announces the
members of its FY 2022 Service Contract
Inventory Report and FY 2023 Planned
Analysis.

ADDRESSES: USAGM Office of Contracts,
330 Independence Ave. SW,
Washington, DC 20237.

FOR FURTHER INFORMATION CONTACT:

Khilena Adhin, Acquisition Policy
Branch Chief, at conpolicy@usagm.gov,
202-920-2302.

SUPPLEMENTARY INFORMATION: In
accordance with section 743 of division
C of the Consolidated Appropriations
Act of 2010, the U.S. Agency for Global
Media (USAGM) is publishing this
notice to advise the public of the
availability of its FY 2022 Service
Contract Inventory Report and FY 2023
Planned Analysis. They are available on
the USAGM website, through the
following link: <https://www.usagm.gov/our-work/strategy-and-results/strategic-priorities/research-reports/service-contract-inventory/>. The service contract
inventory provides information on
service contract actions over \$25,000
made in FY 2022. The information is
organized by function to show how
contracted resources are distributed
throughout the Agency. The inventory
has been developed in accordance with
guidance on service contract inventories
issued on November 5, 2010 and on
December 19, 2011 by the Office of

Management and Budget, Office of
Federal Procurement Policy (OFPP).

Dated: February 28, 2024.

Armanda Matthews,

*Program Support Specialist, U.S. Agency for
Global Media.*

[FR Doc. 2024-04475 Filed 3-1-24; 8:45 am]

BILLING CODE 8610-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting of the Clinical Laboratory Improvement Advisory Committee

AGENCY: Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting for the Clinical
Laboratory Improvement Advisory
Committee (CLIAC). This is a virtual
meeting. It is open to the public, limited
only by the number of webcast lines
available. Time will be available for
public comment, and the public is also
welcome to submit written comments in
advance of the meeting (see the public
participation section below).

DATES: The meeting will be held on
April 10, 2024, from 10 a.m. to 6 p.m.,
EDT.

ADDRESSES: This is a virtual meeting.
Meeting times are tentative and subject
to change. The confirmed meeting
times, agenda items, and meeting
materials, including instructions for
accessing the live meeting broadcast,
will be available on the CLIAC website
at <https://www.cdc.gov/cliac>. Check the
website on the day of the meeting for
the web conference link.

FOR FURTHER INFORMATION CONTACT:

Heather Stang, M.S., Senior Advisor for
Clinical Laboratories, Division of
Laboratory Systems, Center for
Laboratory Systems and Response,
Office of Laboratory Science and Safety,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE,
Mailstop V24-3, Atlanta, Georgia
30329-4027. Telephone: (404) 498-
2769; Email: HStang@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Clinical Laboratory
Improvement Advisory Committee
(CLIAC) is charged with providing
scientific and technical advice and
guidance to the Secretary, Department

of Health and Human Services; the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention (CDC); the
Commissioner, Food and Drug
Administration (FDA); and the
Administrator, Centers for Medicare &
Medicaid Services (CMS). The advice
and guidance pertain to general issues
related to improvement in clinical
laboratory quality and laboratory
medicine and specific questions related
to possible revision of the Clinical
Laboratory Improvement Amendments
of 1988 (CLIA) standards. Examples
include providing guidance on studies
designed to improve quality, safety,
effectiveness, efficiency, timeliness,
equity, and patient-centeredness of
laboratory services; revisions to the
standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and
provision of non-regulatory guidelines
to accommodate technological
advances, such as new test methods, the
electronic transmission of laboratory
information, and mechanisms to
improve the integration of public health
and clinical laboratory practices.

Matters to be Considered: The agenda
will include agency updates from CDC,
CMS, and FDA. Presentations and
CLIAC discussions will focus on the
applicability of CLIA personnel
requirements to preanalytic testing, the
role of artificial intelligence and
machine learning in the clinical
laboratory, and the use of clinical
standards to improve laboratory quality.
Agenda items are subject to change as
priorities dictate.

Public Participation

It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
pertinent to agenda items.

Oral Public Comment: Public
comment periods for each agenda item
are scheduled immediately prior to the
Committee discussion period for that
item. In general, each individual or
group requesting to present an oral
comment will be limited to a total time
of five minutes (unless otherwise
indicated). Speakers should email
CLIAC@cdc.gov or notify the contact
person above (see **FOR FURTHER
INFORMATION CONTACT**) at least five
business days prior to the meeting date.

Written Public Comment: CLIAC
accepts written comments until the date
of the meeting (unless otherwise stated).
However, it is requested that comments
be submitted at least five business days
prior to the meeting date so that the

comments may be made available to the Committee for their consideration and public distribution. Written comments should be submitted by email to CLIAC@cdc.gov or to the contact person above. All written comments will be included in the meeting minutes posted on the CLIAC website.

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024-04432 Filed 3-1-24; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Sole Source Cooperative Agreement To Fund Uganda National Health Laboratories and Diagnostic Services (NHLDS)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$10,000,000, for Year 1 funding to NHLDS. The award will strengthen laboratory systems in Uganda by contributing to the attainment of HIV epidemic control and establishing sustainable and integrated systems for quality assured disease diagnostics, monitoring, and surveillance. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2024, through September 29, 2029.

FOR FURTHER INFORMATION CONTACT: Christina Mwangi, Center for Global Health, Centers for Disease Control and Prevention, US Embassy Kampala, US Centers for Disease Control and Prevention, 1577 Ggaba Road, Telephone: 256772139023, Email: mwn0@cdc.gov.

SUPPLEMENTARY INFORMATION: The sole source award will strengthen Uganda's access to quality laboratory services during the scale up of HIV prevention, care, and treatment by supporting implementation of the Uganda National Health Laboratory Services (UNHLS) Policy II (2016) and its Strategic Plan (2020–2025).

NHLDS is in a unique position to conduct this work, as it is the primary stakeholder of laboratory-related policy development, strategic planning, and resources mobilization for the Ministry of Health (MOH). Additionally, NHLDS directly houses and manages the Central Public Health Reference Laboratory (CPHL) which is the national reference laboratory for HIV early infant diagnosis and viral load, national microbiology reference laboratory, national Tuberculosis (TB) reference laboratory, the national laboratory biorepository and national equipment calibration center. Furthermore, the NHLDS is the primary coordinator of the integrated national laboratory specimen transportation network that handles both HIV, TB and outbreak specimen referral across the country.

Summary of the Award

Recipient: Uganda National Health Laboratories and Diagnostic Services (NHLDS).

Purpose of the Award: The purpose of this award is to strengthen laboratory systems in Uganda by contributing to the attainment of HIV epidemic control and establishing sustainable and integrated systems for quality assured disease diagnostics, monitoring, and surveillance.

Amount of Award: For NHLDS, the approximate year 1 funding amount will be \$10,000,000 in Federal Fiscal Year (FFY) 2024 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C. 7601, *et seq.*] and Public Law 110–293 (the Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and Public Law 113–56 (PEPFAR Stewardship and Oversight Act of 2013).

Period of Performance: The period for this award will be September 30, 2024, through September 29, 2029.

Dated: February 26, 2024.

Jamie Legier,

Acting Director, Office of Grants Services, Centers for Disease Control and Prevention.

[FR Doc. 2024-04399 Filed 3-1-24; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Solicitation of Nominations for Appointment to the Communications and Public Engagement Workgroup (CPEW) of the Advisory Committee to the Director (ACD), CDC

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), within the Department of Health and Human Services (HHS), is seeking nominations for membership to the Communications and Public Engagement Workgroup (CPEW) of the Advisory Committee to the Director, CDC. The CPEW workgroup consists of approximately 15 members who are experts in the fields associated with communications, including public relations, health communication, risk communication, communication research, and marketing; community and partner engagement; public health science and practice, including implementation; and behavioral science/behavior change campaigns.

DATES: Nominations for membership on the CPEW workgroup must be received no later than March 28, 2024. Late nominations will not be considered for membership.

ADDRESSES: All nominations (cover letters and curriculum vitae) should be emailed to ACDDirector@cdc.gov with the subject line: “Nomination for CDC ACD Communications and Public Engagement Workgroup.”

FOR FURTHER INFORMATION CONTACT: Kate Galatas, MPH, Senior Communications Specialist, Office of Communications, Centers for Disease Control and Prevention, 1600 Clifton Road (MS H21-11), Atlanta, GA 30329-4027, Telephone: (404) 639-2064; Email: ACDDirector@cdc.gov.

SUPPLEMENTARY INFORMATION:

Background: The purpose of the ACD, CDC Advisory Committee to the Director shall (1) make recommendations to the Director regarding ways to prioritize the activities of the agency in alignment with the CDC Strategic Plan required under section 305(c); H.R. 2617–1252; (2) advise on ways to achieve or improve performance metrics in relation to the CDC Strategic Plan, and other relevant metrics, as appropriate; (3) provide advice and recommendations on the development of the Strategic Plan, and any subsequent updates, as